<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305539</url>
  </required_header>
  <id_info>
    <org_study_id>P041203</org_study_id>
    <nct_id>NCT00305539</nct_id>
  </id_info>
  <brief_title>HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis</brief_title>
  <official_title>HECTHOR: A Pilot Multicenter Double-blind Randomised Study of 3 Months Treatment With Humira Added to Steroids in Giant Cell Arteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow
      a faster decrease of steroids dosage and therefore avoid some of the adverse events of
      steroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol consists of a SC injection of adalimumab or placebo every 2 weeks for 10 weeks
      added to steroids
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the influence of an initial treatment of 3 months with adalimumab, 40 mg every other week, in the percentage of patients achieving at 6 months (week 26), a decrease in their corticosteroid treatment to a dose equal or lower than 0,1 mg/kg</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the influence of an initial treatment of 3 months with adalimumab on the total dose of corticosteroids determined by AUC (area under the curve)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the influence of an initial treatment of 3 months with adalimumab on the percentage of patients relapsing at one year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40 mg sc / for 3 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 50 years

          -  ACR criteria for Giant cell arteritis (HUNDER 1990)

          -  Positive Temporal artery biopsy

          -  Plus standard inclusion criteria for Humira protocols

        Exclusion Criteria:

          -  Prednisone treatment for a different disease at a dose &gt;15 mg/day

          -  Corticoid treatment for GCA more than 10 days

          -  GCA treatment with prednisone &gt; 1 mg/kg whatever period of time

          -  GCA treatment with an anti-TNF, MTX, cyclosporine, cyclophosphamide, dapsone or
             steroid bolus

          -  Recent, permanent or transient visual loss due to GCA and the presence of any specific
             visual abnormality (diplopia, hallucination)

          -  Plus standard exclusion criteria for Humira protocols
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Mariette, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bicêtre, APHP, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Giant Cell Arteritis</keyword>
  <keyword>Placebo</keyword>
  <keyword>Anti-TNF</keyword>
  <keyword>Multicenter-randomized-trial</keyword>
  <keyword>Proved GCA according to ACR criteria (HUNDER et al 1990)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

